Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Shares in Zogenix plunge after FDA issues refuse-to-file letter for Fintepla as seizure treatment in Dravet syndrome

firstwordpharmaApril 09, 2019

Tag: Zogenix , FDA , refuse-to-file

PharmaSources Customer Service